Status:
COMPLETED
A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Carcinoma, Hepatocellular
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The primary purpose of this protocol is to determine the effect of BMS-582664 on patients with hepatocellular carcinoma with varying levels of hepatic impairment
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Subjects with a biopsy proven advanced solid tumor
- Subjects with a biopsy proven diagnosis of hepatocellular carcinoma conforming to child pugh classifications A, B, or C
Exclusion
Key Trial Info
Start Date :
July 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2010
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00437424
Start Date
July 1 2007
End Date
June 1 2010
Last Update
May 4 2011
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
University Of Alabama At Birmingham
Birmingham, Alabama, United States, 35294
2
Usc/Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033
3
Case Western Reserve University
Clleveland, Ohio, United States, 44106
4
South Texas Accelerated Research Therapeutics, Llc
San Antonio, Texas, United States, 78229